24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

NCT01590459 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

359

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: VX-509
DRUG: VX-509 matching placebo

Sponsor

Vertex Pharmaceuticals Incorporated